Search General Info
Search Education
Search Partnering Companies
![BIF](/sites/default/files/2023-05/230112-bio-bif-logo-color-horiz.jpg)
2020 BIO Investor Forum Buzz of BIO Finalist
Curevo Vaccine is a US-based clinical stage biotech company dedicated to developing next generation vaccines that bring effectiveness, safety, tolerability, and advanced production capabilities to the market - quickly and efficiently.
Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine has completed Phase I (90 subject trial). Results are showing a promising safety profile and the desired immune responses. CRV-101 is inducing a robust vaccine specific and dose dependent antibody immune response. Anti-gE antibody geometric mean concentrations remain well above pre-vaccination levels at 1 year across all dosing cohorts.
We are targeting a unique position in the $4B+ Varicella Zoster Virus vaccine market today, growing to $21B by 20301.
On the strength of our clinical data and pre-clinical pipeline and unmet market opportunity worldwide, we are looking for partners and investors to support the next stage of clinical development.
Curevo Vaccine is a US-based clinical stage biotech company dedicated to developing next generation vaccines that bring effectiveness, safety, tolerability, and advanced production capabilities to the market - quickly and efficiently.
Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine has completed Phase I (90 subject trial). Results are showing a promising safety profile and the desired immune responses. CRV-101 is inducing a robust vaccine specific and dose dependent antibody immune response. Anti-gE antibody geometric mean concentrations remain well above pre-vaccination levels at 1 year across all dosing cohorts.
We are targeting a unique position in the $4B+ Varicella Zoster Virus vaccine market today, growing to $21B by 20301.
On the strength of our clinical data and pre-clinical pipeline and unmet market opportunity worldwide, we are looking for partners and investors to support the next stage of clinical development.
![](/sites/default/files/hubb_images/2996/attachments/%2520-%2520f1_Curevo_20Vaccine_20Inc__962a8d6f.jpg)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Washington
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
CRV-101 for the prevention of Zoster (Shingles)
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
![photo](/sites/default/files/hubb_images/2996/photos/user1.Simeon.09f669e5.jpg)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved